Research & Development
Drug Discovery and Development
Enzo launches RNA gene expression platform for HPV
The platform's products combine sequence-specific probes with Enzo's LoopRNA in situ hybridization (ISH) technology, enabling the products to detect target genes in tissue or cell samples while preserving the morphology, Enzo said. This study of single cells within their native tissue environment, called spatial biology, helps scientists characterize and understand disease, Enzo added.
September 25, 2022
Lunaphore, Nucleai to provide AI-based spatial biology analysis
Combining Lunaphore's Comet hyperplex staining and imaging platform, a fully automated sequential immunofluorescence (seqIF) instrument, with Nucleai's Atom artificial-intelligence (AI) spatial biology platform will enable the companies to generate new insights from tissue biopsies and provide labs with an integrated end-to-end spatial biology workflow.
September 8, 2022
BD, Labcorp to develop flow cytometry CDx
Specifically, the agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners.
August 8, 2022
Nucleai, Ultivue to partner on AI-based drug development platform
Under a comarketing agreement, the firms will integrate Nucleai's AI spatial models with Ultivue's imaging technology with the aim of speeding drug development.
June 5, 2022
Stilla and Promega sign comarketing agreement
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
April 7, 2022
PathAI, GSK partner to accelerate research, drug development
Under the agreement, GSK will gain access to PathAI's technologies in digital pathology, including its artificial intelligence-based measurement of NASH (AIM-NASH) tool, which provides AI-based NASH scoring.
April 4, 2022
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
AbbVie, Scripps Research to collaborate on COVID-19 treatments
The initial research program was conducted at Calibr, Scripps Research's drug discovery and development division, and received funding from the Bill & Melinda Gates Foundation.
March 14, 2022
Precision Medicine Institute to host show on AI and diagnostics
Attendees will see how AI developed by biotech companies are used in daily applications that support patient care, as well as drug discovery, targeting, and screening. The event will showcase the latest developments and trends in AI.
January 24, 2022
C2N Diagnostics debuts blood test to ID Alzheimer's disease
Samples from PrecivityAD are sent to the company's lab in St. Louis. Development of the test was supported by $2.8 million in funding from the Alzheimer's Drug Discovery Foundation over the past decade.
October 29, 2020
Scipher, Galapagos partner to develop IBD treatments
The two companies will jointly validate multiple IBD targets discovered by Scipher. The partnership will leverage the precision medicine firm's proprietary, artificial intelligence (AI)-driven Network Medicine Platform and molecular patient data.
August 12, 2020
Illumina Accelerator announces new genomics startups
Of the seven companies, three will mark the inaugural funding cycle of Illumina Accelerator Cambridge, U.K., while four other firms will join as part of the eleventh funding cycle in the San Francisco Bay Area, according to Illumina.
June 22, 2020
Twist Bioscience, Sophia Genetics partner on NGS, DNA analysis
South San Francisco, CA-based Twist has developed a DNA synthesis platform that involves manufacturing synthetic DNA for use in NGS preparation and the development of antibody libraries that inform drug discovery. Sophia Genetics, which has offices in the U.S., Switzerland, and France, has developed an AI-powered platform for DNA analysis.
February 25, 2020
Page 1 of 2